The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | INDEPENDENCE trial: luspatercept in patients with myelofibrosis and anemia on JAK2 inhibitor therapy
Haifa Kathrin Al-Ali, MD, University Hospital Halle, Halle, Germany, provides insight into the Phase III INDEPENDENCE (NCT04717414) trial, which evaluated the combination of ruxolitinib or fedratinib with luspatercept in patients with myelofibrosis. Dr Kathrin Al-Ali highlights that this combination may allow adequate dosing of ruxolitinib or fedratinib, which are effective for symptoms and spleen-related issues but often worsen anemia and transfusion dependence. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
